Lataa...
Interstitial Lung Disease Induced by Pazopanib Treatment
Although pneumothorax has been reported to be a major pulmonary adverse event in patients treated with pazopanib, a multikinase inhibitor, drug-induced interstitial lung disease (DILD) has not been reported. A 74-year-old Japanese man who received pazopanib for the treatment of femoral leiomyosarcom...
Tallennettuna:
| Julkaisussa: | Intern Med |
|---|---|
| Päätekijät: | , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
The Japanese Society of Internal Medicine
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5313429/ https://ncbi.nlm.nih.gov/pubmed/28050004 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|